<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="case-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">dG3RZRRMt3GCCtGs3JvdgTJ</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2013000100019</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(13)10000100019</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2013000100019</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Arterite de Takayasu: estenose p&#243;s implante de stent convencional e farmacol&#243;gico</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Soeiro</surname>
            <given-names>Alexandre de Matos</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>Ana Luiza</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Henares</surname>
            <given-names>Bruna Bernardes</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Henrique Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lima</surname>
            <given-names>Felipe Gallego</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Serrano Jr</surname>
            <given-names>Carlos Vicente</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Instituto do Cora&#231;&#227;o</institution>
        <institution content-type="orgdiv1">Unidade Cl&#237;nica de Coronariopatia Aguda </institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Instituto do Cora&#231;&#227;o</institution>
        <institution content-type="orgdiv1">Unidade Cl&#237;nica de Emerg&#234;ncia </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2013</year>
      </pub-date>
      <volume>100</volume>
      <issue>1</issue>
      <fpage>e8</fpage>
      <lpage>e11</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <pub-date publication-format="electronic" date-type="pub">
        <day>29</day>
        <month>01</month>
        <year>2013</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>RELATO DE CASO</bold>
    </p>
    <p>
      <bold>Arterite de Takayasu: estenose p&#243;s implante de stent convencional e farmacol&#243;gico</bold>
    </p>
    <p>
      <bold>Alexandre de Matos Soeiro<sup>II</sup>; Ana Luiza Pinto<sup>II</sup>; Bruna Bernardes Henares<sup>II</sup>; Henrique Barbosa Ribeiro<sup>I</sup>; Felipe Gallego Lima<sup>I</sup>; Carlos Vicente Serrano Jr<sup>I</sup></bold>
    </p>
    <p><sup>I</sup>Unidade Cl&#237;nica de Coronariopatia Aguda (UCCA) - Instituto do Cora&#231;&#227;o (InCor) - HCFMUSP </p>
    <p><sup>II</sup>Unidade Cl&#237;nica de Emerg&#234;ncia - Instituto do Cora&#231;&#227;o (InCor) - HCFMUSP, S&#227;o Paulo, SP - Brasil </p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p><bold>Palavras-chave:</bold> Arterite de Takayasu, Stents; Stents Farmacol&#243;gicos, Revasculariza&#231;&#227;o Mioc&#225;rdica.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Arterite de Takayasu (AT) &#233; uma arterite inflamat&#243;ria cr&#244;nica de etiologia desconhecida que acomete grandes vasos, principalmente aorta e seus principais ramos, vasos pulmonares e coron&#225;rias<sup>1</sup>. Devido &#224; raridade dos casos a monitora&#231;&#227;o da atividade da doen&#231;a e o melhor esquema terap&#234;utico ainda t&#234;m sido um desafio para todos os que tratam esses pacientes. Especificamente em casos de s&#237;ndromes coron&#225;rias agudas (SCA), a melhor forma de tratamento intervencionista mant&#233;m-se indefinido. Algumas s&#233;ries de casos apresentam sua experi&#234;ncia com angioplastia coron&#225;ria (ATC) e/ou cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica (CRM), por&#233;m com pouca consist&#234;ncia<sup>1</sup>. Nesse contexto, o relato da evolu&#231;&#227;o de uma mesma paciente submetida a implante de stent coron&#225;rio convencional e, posteriormente, farmacol&#243;gico de forma consecutiva, associado &#224; estenose coron&#225;ria intrastent nos dois procedimentos na aus&#234;ncia de inflama&#231;&#227;o, com subsequente realiza&#231;&#227;o de CRM, &#233; &#250;nico e refor&#231;a a dificuldade de manejo de SCA nessa doen&#231;a.</p>
    <p>
      <bold>Relato do Caso</bold>
    </p>
    <p>Trata-se de paciente de 33 anos, sexo feminino, branca, natural e procedente da cidade de S&#227;o Paulo, com diagn&#243;stico pr&#233;vio de AT, que compareceu ao servi&#231;o de emerg&#234;ncia com queixa de dor precordial em aperto de moderada intensidade, irradiada para membro superior esquerdo, ao repouso, associada &#224; dispneia leve e sudorese h&#225; um dia. Referia quadro pr&#233;vio de angina inst&#225;vel h&#225; doze meses quando foi colocado stent convencional 5,0 x 12,0 mm em tronco de coron&#225;ria esquerda e, novamente h&#225; seis meses, quando, devido &#224; reestenose intrastent (<xref ref-type="fig" rid="a19fig01">Figura 1</xref>), foi realizada nova ATC com stent farmacol&#243;gico 3,5 x 18 mm de tipo <italic>Cypher</italic> (recoberto com sirolimus) no mesmo segmento coronariano. Ap&#243;s o procedimento, foi realizado ultrassonografia intracoron&#225;ria que evidenciou boa aposi&#231;&#227;o e expans&#227;o do stent e &#225;rea luminal m&#237;nima de 11,6 mm<sup>2</sup>. Negava demais comorbidades e fatores de risco. Fazia uso cr&#244;nico de metrotexate 25 mg/semana, prednisona 10 mg/dia, clopidogrel 75 mg/dia, AAS 100 mg/dia, atenolol 100 mg/dia e ranitidina 300 mg/dia. </p>
    <p content-type="asset">
      <fig id="a19fig01">
        <graphic xlink:href="1678-4170-abc-100-01-00e8-00019-gf01.jpg"/></fig>
    </p>
    <p>Ao exame f&#237;sico da admiss&#227;o, encontrava-se em bom estado geral, eupneica (frequ&#234;ncia respirat&#243;ria = 16 incurs&#245;es por minuto), com frequ&#234;ncia card&#237;aca de 70 batimentos por minutos, satura&#231;&#227;o arterial perif&#233;rica de oxig&#234;nio de 96%, press&#227;o arterial de 118 x 56 mmHg em membro superior direito e 130 x 60 mmHg em membro superior esquerdo, ictus n&#227;o vis&#237;vel e palp&#225;vel com uma polpa digital no quarto espa&#231;o intercostal normoposicionado sob a linha hemiclavicular esquerda, presen&#231;a de bulhas r&#237;tmicas com sopro sist&#243;lico ejetivo +2/+6 em foco a&#243;rtico e murm&#250;rios vesiculares presentes bilateralmente &#224; ausculta pulmonar sem ru&#237;dos advent&#237;cios. Aus&#234;ncia de fr&#234;mitos &#224; palpa&#231;&#227;o card&#237;aca. Pulsos encontravam-se presentes bilateralmente, amplos e sim&#233;tricos. Estase jugular ausente bilateralmente a 45 graus. Nesse momento foi feito diagn&#243;stico de SCA.</p>
    <p>Eletrocardiograma solicitado mostrou ritmo sinusal sem altera&#231;&#245;es isqu&#234;micas agudas. Radiografia de t&#243;rax sem altera&#231;&#245;es evidentes em campos pulmonares e &#225;rea card&#237;aca com tamanho normal. Ecocardiograma transtor&#225;cico mostrou &#225;trio esquerdo de 38 mm, fra&#231;&#227;o de eje&#231;&#227;o de ventr&#237;culo esquerdo de 62% sem disfun&#231;&#227;o segmentar, sem demais altera&#231;&#245;es. Angiotomografia mostrou estenose carot&#237;dea bilateral maior que 50% e aus&#234;ncia de estenose subcl&#225;via. Exames laboratoriais evidenciaram prote&#237;na-C reativa de 2,34 mg/L, velocidade de hemossedimenta&#231;&#227;o de 16 mm e marcadores de necrose mioc&#225;rdica (CKMB e troponina) negativos. Optou-se por realiza&#231;&#227;o de coronariografia <xref ref-type="fig" rid="a19fig02">(Figura 2</xref>) que mostrou reestenose intrastent com obstru&#231;&#227;o de 90% em tronco de coron&#225;ria esquerda, sendo optado por realiza&#231;&#227;o de CRM.</p>
    <p content-type="asset">
      <fig id="a19fig02">
        <graphic xlink:href="1678-4170-abc-100-01-00e8-00019-gf02.jpg"/></fig>
    </p>
    <p>A paciente foi submetida &#224; realiza&#231;&#227;o de CRM com circula&#231;&#227;o extracorp&#243;rea e implante art&#233;ria tor&#225;cica interna esquerda <italic>in situ</italic> em art&#233;ria descente anterior e ponte de veia safena em art&#233;ria diagonalis. Ap&#243;s oito dias, a paciente recebeu alta hospitalar assintom&#225;tica, em uso de prednisona 10 mg/dia, micofenolato mofetila 1500 mg/dia, cloroquina 250 mg/dia, atenolol 50 mg/dia, sinvastatina 20 mg/dia, AAS 100 mg/dia e ranitidina 300 mg/dia. </p>
    <p>Ap&#243;s seis meses de seguimento, a paciente encontrava-se assintom&#225;tica. Nessa ocasi&#227;o, optou-se por realiza&#231;&#227;o de angiotomografia de art&#233;ria coron&#225;rias para visualiza&#231;&#227;o dos enxertos, sendo observada pat&#234;ncia dos mesmos, sem novos pontos de oclus&#227;o arterial. </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>O diagn&#243;stico de AT foi realizado baseado nos crit&#233;rios do <italic>American College of Rheumatology</italic> de 1990 e, portanto, estabelecido atrav&#233;s da presen&#231;a de idade menor de 40 anos, diferen&#231;a de press&#227;o arterial maior que 10 mmHg entre membros, sopro a&#243;rtico e anormalidade no arteriograma<sup>1</sup>.</p>
    <p>A AT acomete principalmente mulheres (90% dos casos) com idade entre 10 e 40 anos. Na literatura, &#233; descrita a presen&#231;a de alguma forma de doen&#231;a coron&#225;ria em 6% a 30% dos pacientes com AT<sup>1-4</sup>. Sua patog&#234;nese ainda n&#227;o est&#225; completamente elucidada, sendo atualmente considerada resultado da inflama&#231;&#227;o autoimune cr&#244;nica em grandes art&#233;rias, al&#233;m de estarem associados outros fatores envolvidos, como agentes infecciosos e predisposi&#231;&#227;o gen&#233;tica. O desenvolvimento da doen&#231;a parece ocorrer em duas fases: um primeiro per&#237;odo em que h&#225; eleva&#231;&#227;o dos marcadores inflamat&#243;rios, seguido por uma fase cr&#244;nica com o desenvolvimento de insufici&#234;ncia vascular<sup>3</sup>.</p>
    <p>N&#227;o se sabe com exatid&#227;o o momento de ocorr&#234;ncia de les&#245;es coronarianas. A maior parte dos estudos afirma que h&#225; correla&#231;&#227;o entre quadros de SCA e eleva&#231;&#227;o de marcadores inflamat&#243;rios com prote&#237;na-C reativa e/ou velocidade de hemossedimenta&#231;&#227;o<sup>1</sup>. No entanto, da mesma maneira que no caso apresentado, alguns relatos de caso referem n&#227;o haver rela&#231;&#227;o direta entre inflama&#231;&#227;o ativa e o sintoma coronariano<sup>5</sup>.</p>
    <p>A agress&#227;o pela doen&#231;a pode ocorrer desde angina est&#225;vel a infarto agudo do mioc&#225;rdio, devendo ser rapidamente reconhecida para estabelecimento de adequada imunossupress&#227;o junto &#224; terap&#234;utica cardiol&#243;gica espec&#237;fica, podendo alterar o progn&#243;stico<sup>4</sup>. As descri&#231;&#245;es de casos na literatura cient&#237;fica s&#227;o poucas, por&#233;m a isquemia mioc&#225;rdica &#233; uma das principais causas de morte pela doen&#231;a, com mortalidade podendo chegar a 50% em at&#233; cinco anos de seguimento<sup>3</sup>.</p>
    <p>Assim como relatado no caso, o acometimento de &#243;stios das art&#233;rias coron&#225;rias direita e esquerda s&#227;o os achados mais comuns, encontrados em 87,5% dos casos de AT com comprometimento coron&#225;rio. Nesses casos, a obstru&#231;&#227;o luminal &#233; causada pela extens&#227;o da prolifera&#231;&#227;o intimal e contra&#231;&#227;o fibr&#243;tica das camadas m&#233;dia e advent&#237;cia da aorta ascendente. No entanto, les&#245;es coron&#225;rias podem tamb&#233;m ocorrer em segmentos mais distais, uma vez que a inflama&#231;&#227;o cr&#244;nica da AT pode contribuir com o desenvolvimento de aterosclerose precoce<sup>4</sup>. O diagn&#243;stico geralmente &#233; realizado pelo quadro cl&#237;nico associado &#224; coronariografia, por&#233;m estudos recentes t&#234;m demonstrado excelente acur&#225;cia com a angiotomografia coron&#225;ria em casos de AT<sup>4</sup>.</p>
    <p>O implante de stent convencional em pacientes com AT pode levar &#224; reestenose em at&#233; 78% das vezes, assim como no caso descrito. As descri&#231;&#245;es de uso de stents farmacol&#243;gicos nesse grupo de doentes s&#227;o raras, no entanto, os resultados apresentados tamb&#233;m demonstram elevados &#237;ndices de reestenose nos seguimentos a curto e longo prazo, questionando a seguran&#231;a de seu uso em pacientes com AT. Alguns autores sugerem que esse tipo de stent poderia ser usado apenas como ponte at&#233; que se alcance uma melhor imunossupress&#227;o do doente e seja efetuada a CRM em momento adequado<sup>2,4,6,7</sup>.</p>
    <p>Yokota e cols.<sup>4</sup> relataram um caso de uma mulher de 52 anos de idade submetida a quatro angioplastias coron&#225;rias de art&#233;ria descendente anterior, sendo a primeira com stent convencional e as outras tr&#234;s com stent farmacol&#243;gico. Observou-se reestenose por tr&#234;s vezes, sendo que somente na &#250;ltima tentativa a paciente evoluiu sem novas obstru&#231;&#245;es. Segundo os autores, neste &#250;ltimo procedimento, a associa&#231;&#227;o de doses mais altas de corticoide pode ter sido respons&#225;vel pela pat&#234;ncia do vaso<sup>4,8</sup>. Por&#233;m, no caso relatado, mostramos a ocorr&#234;ncia de reestenose intrastent mesmo com a presen&#231;a de atividade inflamat&#243;ria discreta, ratificando a controv&#233;rsia sobre o implante de stents farmacol&#243;gicos nesses pacientes.</p>
    <p>Em rela&#231;&#227;o &#224; CRM, o m&#233;todo de revasculariza&#231;&#227;o ideal ainda n&#227;o foi estabelecido. A presen&#231;a de les&#227;o ostial com comprometimento da aorta e poss&#237;vel acometimento de art&#233;rias subcl&#225;vias torna a decis&#227;o complexa. Em contraste com a maioria das CRM's realizadas, em pacientes com AT o principal enxerto utilizado &#233; a veia safena, exceto quando h&#225; muita calcifica&#231;&#227;o na aorta. A sobrevida relatada com esse tipo de implante anastomosado &#224; art&#233;ria descendente anterior chega a 80% em 10 anos, com sobrevida livre de eventos de 77%. O uso da art&#233;ria tor&#225;cica interna <italic>in situ</italic> n&#227;o &#233; proibitivo, mas deve ser evitado e, quando realizado, deve-se avaliar a pat&#234;ncia das art&#233;rias subcl&#225;vias com exames de imagem antes da CRM<sup>1,9</sup>. No caso descrito, apesar do uso da art&#233;ria tor&#225;cica interna esquerda <italic>in situ</italic>, a paciente evoluiu sem sintomas e com pat&#234;ncia adequada do enxerto ap&#243;s seis meses de seguimento.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>O presente caso mostra que em pacientes com AT com quadro de SCA, o r&#225;pido diagn&#243;stico e o tratamento precoce podem contribuir enormemente para a mudan&#231;a do progn&#243;stico. A dosagem de marcadores inflamat&#243;rios pode n&#227;o ter correla&#231;&#227;o direta com o quadro de SCA, sendo ostial a maioria das les&#245;es coronarianas, o que imp&#245;e maior risco ao paciente. Apesar de controversa devido &#224; falta de estudos, neste paciente a realiza&#231;&#227;o de ATC com stent convencional e farmacol&#243;gico mostrou-se ineficaz e seguiu-se de reestenose no per&#237;odo de seis meses na aus&#234;ncia de inflama&#231;&#227;o significativa. Mesmo sendo pouco relatada na literatura, a CRM com enxerto derivado de art&#233;ria tor&#225;cica interna <italic>in situ</italic> mostrou-se seguro, desde que seja avaliada a pat&#234;ncia da art&#233;ria subcl&#225;via no per&#237;odo pr&#233;-operat&#243;rio e mantida a imunossupress&#227;o adequada a longo prazo.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Alexandre de Matos Soeiro </p>
        <p> Rua Maranh&#227;o, 680 / 81 - Santa Paula </p>
        <p> CEP 09530-440 - S&#227;o Caetano do Sul, SP, Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="alexandre.soeiro@bol.com.br">alexandre.soeiro@bol.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 02/05/12; revisado em 12/08/12; aceito em 26/09/12.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Rav-Acha M, Plot L, Peled N, Amital H. Coronary involvement in Takayasu's arteritis. Autoimmun Rev. 2007;6(8):566-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Coronary involvement in Takayasu's arteritis</article-title>
          <source>Autoimmun Rev</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>566</fpage>
          <lpage>71</lpage>
          <issue>8</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rav-Acha</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Plot</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Peled</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Amital</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Gelape CL, Alvarenga FC, Figueroa CC, Ribeiro AL. Tratamento de estenose de tronco de coron&#225;ria esquerda na arterite de Takayasu. Rev Bras Reumatol. 2007;47(5):390-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tratamento de estenose de tronco de coron&#225;ria esquerda na arterite de Takayasu</article-title>
          <source>Rev Bras Reumatol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>390</fpage>
          <lpage>3</lpage>
          <issue>5</issue>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gelape</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Alvarenga</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Figueroa</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Soto ME, Espinola-Zavaleta N, Ramirez-Quito O, Reyes PA. Echocardiographic follow-up of patients with Takayasu's arteritis: five-year survival. Echocardiography. 2006;23(5):353-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiographic follow-up of patients with Takayasu's arteritis: five-year survival</article-title>
          <source>Echocardiography</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>353</fpage>
          <lpage>9</lpage>
          <issue>5</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Soto</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Espinola-Zavaleta</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ramirez-Quito</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Reyes</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Yokota K, Shimpo M, Iwata T, Hirose M, Ikemoto T, Ohya K, et al. A case of Takayasu arteritis with repeated coronary artery restenosis after drug-eluting stent implantation successfully treated with a combination of steroids. Intern Med. 2012;51(7):739-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A case of Takayasu arteritis with repeated coronary artery restenosis after drug-eluting stent implantation successfully treated with a combination of steroids</article-title>
          <source>Intern Med</source>
          <date>
            <year>2012</year>
          </date>
          <fpage>739</fpage>
          <lpage>43</lpage>
          <issue>7</issue>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yokota</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shimpo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Iwata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirose</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ikemoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohya</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol. 2002;55(7):481-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Takayasu arteritis: a review</article-title>
          <source>J Clin Pathol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>481</fpage>
          <lpage>6</lpage>
          <issue>7</issue>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Johnston</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Lock</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Gompels</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Lee HK, Namgung J, Choi WH, Choe H, Kwon SU, Doh JH, et al. Stenting of the left main artery in a patient with Takayasu's Arterits. Korean Circ J. 2011;41(1):34-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Stenting of the left main artery in a patient with Takayasu's Arterits</article-title>
          <source>Korean Circ J</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>34</fpage>
          <lpage>7</lpage>
          <issue>1</issue>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Namgung</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Choe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kwon</surname>
              <given-names>SU</given-names>
            </name>
            <name>
              <surname>Doh</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis: a study of 32 North American patients. Medicine (Baltimore). 1985;64(2):89-99.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Takayasu arteritis: a study of 32 North American patients</article-title>
          <source>Medicine</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>89</fpage>
          <lpage>99</lpage>
          <issue>2</issue>
          <volume>64</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hall</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Barr</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lie</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Stanson</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Kazmier</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Hunder</surname>
              <given-names>GG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Sakai H, Oyama N, Kishimoto N, Takahashi M, Urasawa K, Tsutsui H. Revascularization of malignant coronary instent restenosis resulting from Takayasu's arteritis using sirolimus-eluting stents. Int Heart J. 2006;47(5):795-801.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Revascularization of malignant coronary instent restenosis resulting from Takayasu's arteritis using sirolimus-eluting stents</article-title>
          <source>Int Heart J</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>795</fpage>
          <lpage>801</lpage>
          <issue>5</issue>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sakai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Oyama</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kishimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Urasawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsutsui</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Endo M, Tomizawa Y, Nishida H, Aomi S, Nakazawa M, Tsurumi Y, et al. Angiographic findings and surgical treatments of coronary artery involvement in Takayasu arterits. J Thorac Cardiovasc Surg. 2003;125(3):570-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Angiographic findings and surgical treatments of coronary artery involvement in Takayasu arterits</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>570</fpage>
          <lpage>7</lpage>
          <issue>3</issue>
          <volume>125</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Endo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tomizawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nishida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Aomi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakazawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsurumi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Takayasu arteritis: stenosis after bare-metal and drug-eluting stent implantation</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>CASE REPORT</bold>
      </p>
      <p>
        <fn id="enda-body2">
          <label>
            <bold>Takayasu arteritis: stenosis after bare-metal and drug-eluting stent implantation</bold>
          </label>
          <p>
            <bold>Alexandre de Matos Soeiro<sup>II</sup>; Ana Luiza Pinto<sup>II</sup>; Bruna Bernardes Henares<sup>II</sup>; Henrique Barbosa Ribeiro<sup>I</sup>; Felipe Gallego Lima<sup>I</sup>; Carlos Vicente Serrano Jr<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Unidade Cl&#237;nica de Coronariopatia Aguda (UCCA) - Instituto do Cora&#231;&#227;o (InCor) - HCFMUSP</p>
      <p><sup>II</sup>Unidade Cl&#237;nica de Emerg&#234;ncia - Instituto do Cora&#231;&#227;o (InCor) - HCFMUSP, S&#227;o Paulo, SP - Brasil </p>
      <p>Mailing Address</p>
      <p><bold>Keywords:</bold> Takayasy Arteritis; Stents; Drug-Eluting Stents; Myocardial Revascularization.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Takayasu arteritis (TA) is a chronic inflammatory arteritis of unknown etiology that affects large vessels, especially the aorta and its main branches, pulmonary vessels and coronaries<sup>1</sup>. Due to the scarcity of cases, the monitoring of disease activity and best treatment regimen remain a challenge for all professional who treat these patients. Specifically in cases of acute coronary syndrome (ACS), the best interventional treatment remains undefined. Some case series have shown their experience with percutaneous transluminal coronary angioplasty (PTCA) and/or coronary artery bypass grafting (CABG), but with little consistence<sup>1</sup>. In this context, the story of a single patient's evolution submitted to conventional coronary stenting and subsequently, consecutive drug-eluting stent implants, associated with in-stent coronary stenosis at the two procedures in the absence of inflammation, with subsequent implementation of CABG, is unique and reinforces the difficulty of managing ACS in the presence of this disease. </p>
      <p>
        <bold>Case Report</bold>
      </p>
      <p>This was a 33-year-old Caucasian female patient, born and raised in S&#227;o Paulo, with a previous diagnosis of TA, treated at the emergency department after complaining of precordial gripping pain of moderate intensity, radiating to the left arm at rest, associated with mild dyspnea and sweating for one day. She reported a previous picture of unstable angina twelve months before, when a 5.0 x 12.0 mm bare-metal stent was implanted in left main coronary artery, and again six months before, when, due to in-stent restenosis (<xref ref-type="fig" rid="en_a19fig01-body2">Figure 1</xref>) a new PTCA was performed with a 3.5 x 18 mm Cypher DES (sirolimus coated) in the same coronary segment. </p>
      <p content-type="asset">
        <fig id="en_a19fig01-body2">
          <graphic xlink:href="1678-4170-abc-100-01-00e8-00019-gf01-en.jpg"/></fig>
      </p>
      <p>After the procedure, intracoronary ultrasound was performed, which showed good stent apposition and expansion and minimal luminal area of 11.6 mm<sup>2</sup>. She denied other comorbidities and risk factors. She took methotrexate 25 mg / week, prednisone 10 mg/day, clopidogrel 75 mg/day, ASA 100 mg/day, atenolol 100 mg/day and ranitidine 300 mg/day. </p>
      <p>At physical examination on admission, she was in good general status, eupneic (respiratory rate = 16 breaths per minute), with a heart rate of 70 beats per minute, peripheral arterial oxygen saturation of 96%, blood pressure of 118 mmHg x 56 in the right arm and 130 x 60 mm Hg in the left arm, ictus not visible but palpable with fingertip in the normal position at the fourth intercostal space under the left midclavicular line, rhythmic heart sounds with aortic systolic ejection murmur +2 / +6 and bilateral breath sounds on auscultation with no adventitious sounds. There was no murmur at heart palpation. Pulses were bilateral, wide and symmetrical. Jugular stasis was absent bilaterally at 45 degrees. At this time, ACS was diagnosed.</p>
      <p>The electrocardiogram showed sinus rhythm with no acute ischemic alterations. The chest radiography showed no obvious alterations in heart size and normal lungs. The transthoracic echocardiogram showed a left atrium of 38 mm, left ventricular ejection fraction of 62% with no segmental dysfunction, and no other alterations. The angiography showed bilateral carotid stenosis &gt; 50% and absence of subclavian stenosis. Laboratory tests showed C-reactive protein levels of 2.34 mg/L, erythrocyte sedimentation rate of 16 mm and negative markers of myocardial necrosis (CK-MB and troponin). A coronary angiography (<xref ref-type="fig" rid="en_a19fig02-body2">Figure 2</xref>) was performed, which showed in-stent restenosis with 90% obstruction in the left main coronary artery and we chose to perform another CABG.</p>
      <p content-type="asset">
        <fig id="en_a19fig02-body2">
          <graphic xlink:href="1678-4170-abc-100-01-00e8-00019-gf02-en.jpg"/></fig>
      </p>
      <p>The patient underwent the CABG with cardiopulmonary bypass and <italic>in situ</italic> left internal mammary artery implant to the anterior descending artery and saphenous vein graft to the diagonal artery. After eight days, the patient was discharged, asymptomatic, while on prednisone 10 mg / day, mycophenolate mofetil 1500 mg/day, chloroquine 250 mg / day, atenolol 50 mg/day, simvastatin 20 mg/day, aspirin 100 mg/day and ranitidine 300 mg/day. </p>
      <p>After a six-month follow up, the patient was asymptomatic. On that occasion, a coronary artery angiotomography was performed for graft assessment and their patency was verified, with no new points of arterial occlusion. </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The diagnosis of TA was carried out based on the criteria of the American College of Rheumatology of 1990, and thus established by the presence of age &lt; 40 years, difference of blood pressure &gt; 10 mmHg between limbs, aortic murmur and arteriogram alteration<sup>1</sup>.</p>
      <p>TA affects mainly women (90% of cases) aged 10 to 40 years. In the literature, the presence of some type of coronary disease is described in 6% to 30% of patients with TA<sup>1-4</sup>. Its pathogenesis is not yet completely understood and is currently considered the result of chronic autoimmune inflammation of large arteries, in addition to being associated with other factors, such as infectious agents and genetic predisposition. Disease development appears to occur in two phases: the first phase, in which there is elevation of inflammatory markers, followed by a chronic phase, with the development of vascular failure<sup>3</sup>. </p>
      <p>The precise timing of coronary lesions is not known. Most studies say there is a correlation between pictures of ACS and elevated inflammatory markers with C-reactive protein and/or erythrocyte sedimentation rate<sup>1</sup>. However, as in our case, some case reports refer no direct association between active inflammation and coronary symptom<sup>5</sup>.</p>
      <p>Injury caused by the disease can vary from stable angina to acute myocardial infarction and should be quickly recognized, so adequate immunosuppression therapy can be initiated together with specific cardiac therapy, which may change prognosis<sup>4</sup>. There are few case descriptions in the literature, but myocardial ischemia is a leading cause of death by the disease, with 50% of mortality in five years of follow-up<sup>3</sup>.</p>
      <p>As reported in our case, the involvement of left and right coronary artery ostia are the most common findings, found in 87.5% of cases of TA with coronary involvement. In such cases, luminal obstruction is caused by the extension of intimal proliferation and fibrotic contraction of medial and adventitial layers of the ascending aorta. However, coronary lesions can also occur in more distal segments, as chronic inflammation in TA may contribute to the development of premature atherosclerosis<sup>4</sup>. The diagnosis is usually made through the clinical presentation associated with coronary angiography, but recent studies have demonstrated excellent accuracy with coronary angiography in cases of TA<sup>4</sup>. </p>
      <p>Conventional stenting in patients with TA may lead to restenosis in up to 78% of the cases, as the one described here. Descriptions of drug-eluting stent use in this group of patients are rare; however, the results also show high rates of restenosis in the short and long term, which raises questions about the safety of its use in patients with TA. Some authors suggest that this type of stent could be used only as a bridge to reach better patient immunosuppression and that CABG should be performed at the appropriate time<sup>2,4,6,7</sup>.</p>
      <p>Yokota et al<sup>4</sup> reported the case of a 52-year-old woman submitted to four coronary angioplasties of the ADA, the first with a bare-metal stent and the other three with drug-eluting stents. Restenosis was observed three times, and only on the last attempt the patient developed no new obstructions. According to the authors, in this latter procedure, the combination of higher doses of corticosteroids may have been responsible for vessel patency<sup>4,8</sup>. However, in our case, we showed the occurrence of in-stent restenosis even with the presence of discrete inflammatory activity, confirming the controversy over the implantation of DES in these patients.</p>
      <p>With respect to CABG, the ideal coronary artery bypass method has yet to be established. The presence of ostial lesion with aortic involvement and possible involvement of the subclavian arteries makes the decision a complex one. In contrast with most CABG surgeries performed in patients with TA, the main graft used is the saphenous vein, except when there is a lot of calcification in the aorta. The survival reported with this type of implant anastomosed to the left anterior descending artery reaches 80% in 10 years, with event-free survival of 77%. The use of <italic>in situ </italic>internal thoracic artery is not proscribed, but should be avoided and, when performed, the subclavian artery patency must be assessed by imaging examinations prior to CABG<sup>1,9</sup>. In the case described, regardless of <italic>in situ </italic>use of the left internal thoracic artery, the patient had no symptoms and adequate graft patency after six months of follow up.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>The present case shows that in TA patients with ACS, rapid diagnosis and early treatment can greatly contribute to the change in prognosis. The measurement of inflammatory markers may have no direct correlation with the ACS, with most coronary lesions being ostial ones, which poses a greater risk to the patient. Although controversial due to the lack of studies, performing TCA in patients with conventional and drug-eluting stents showed to be ineffective and was followed by restenosis at six months in the absence of significant inflammation. Even though it is rarely reported in the literature, CABG with <italic>in situ</italic> internal thoracic artery graft was safe, provided that the patency of the subclavian artery is evaluated in the preoperative period and adequate immunosuppression is maintained at long-term.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
